Abstract

Bevacizumab is a chimeric monoclonal human-murine antibody originated from murine monoclonal antibody (muMAb A4.6.1) with the human immunoglobulin IgG1. BVZ binds the extracellular portion of vascular endothelial growth factor receptors (VEGFR), which have tyrosine kinase activity. The mechanism of action of BVZ involves binding to VEGFR, Flt-1 (VEGFR-1) and KDR/Flk-1 (VEGFR-2), inducing homodimerization of two receptor subunits, and, consequently, autophosphorylation of their tyrosine kinase domains located inside the cytoplasm. With the advent of nanostructured systems it is increasingly necessary to look for safe analytical methods, ensuring the reliability of the results obtained by them, becoming essential to ensure the quality of medicines. In this work, the incorporation of bevacizumab in to different drug delivery systems was presented. Moreover, detailed investigation was performed about methods for qualitative and quantitative analyses of bevacizumab, including, biological fluids, and drug delivery systems, were investigated. Most recently high performance liquid chromatography coupled with various detectors, liquid chromatography, mass spectrometry and ELISA were used for this purpose. Thus, this review was performed to evaluate the benefits of bevacizumab carried by nanostructured systems and the analytical methods available for detection and quantification of these drugs.

摘要

贝伐珠单抗是源自鼠单克隆抗体 (muMAb A4.6.1) 和人免疫球蛋白 IgG1 的嵌合单​​克隆人-鼠抗体。BVZ 结合具有酪氨酸激酶活性的血管内皮生长因子受体 (VEGFR) 的细胞外部分。BVZ 的作用机制包括与 VEGFR、Flt-1 (VEGFR-1) 和 KDR/Flk-1 (VEGFR-2) 结合，诱导两个受体亚基的同源二聚化，并因此使它们位于内部的酪氨酸激酶结构域自磷酸化细胞质。随着纳米结构系统的出现，越来越有必要寻找安全的分析方法，以确保其获得的结果的可靠性，这对于确保药物质量变得至关重要。在这项工作中，介绍了将贝伐单抗纳入不同的药物递送系统。此外，对贝伐单抗的定性和定量分析方法进行了详细调查，包括生物体液和药物输送系统。最近，结合各种检测器的高效液相色谱、液相色谱、质谱和 ELISA 用于此目的。因此，本综述旨在评估纳米结构系统携带的贝伐单抗的益处以及可用于检测和量化这些药物的分析方法。为此目的使用质谱法和ELISA。因此，本综述旨在评估纳米结构系统携带的贝伐单抗的益处以及可用于检测和量化这些药物的分析方法。为此目的使用质谱法和ELISA。因此，本综述旨在评估纳米结构系统携带的贝伐单抗的益处以及可用于检测和量化这些药物的分析方法。